Xin Lang Cai Jing·2025-09-25 01:28Core Viewpoint - The recent trading activity and financial performance of Haiprui Pharmaceutical indicate a mixed outlook, with notable fluctuations in financing and stockholder dynamics [1][2]. Financing Activity - On September 24, Haiprui's stock rose by 1.16%, with a trading volume of 41.77 million yuan. The financing buy-in amounted to 4.87 million yuan, while the financing repayment was 5.70 million yuan, resulting in a net financing outflow of 0.83 million yuan [1]. - As of September 24, the total financing and securities lending balance for Haiprui was 258 million yuan, with the financing balance of 256 million yuan accounting for 1.69% of the circulating market value, which is above the 60th percentile of the past year [1]. - In terms of securities lending, Haiprui repaid 6,200 shares and sold 8,500 shares on the same day, with a selling amount of 0.1035 million yuan. The remaining securities lending volume was 10,840 shares, with a balance of 1.32 million yuan, exceeding the 90th percentile of the past year [1]. Financial Performance - For the first half of 2025, Haiprui reported a revenue of 2.817 billion yuan, reflecting a year-on-year decrease of 0.71%. The net profit attributable to shareholders was 422 million yuan, down 36.44% year-on-year [2]. - Since its A-share listing, Haiprui has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [2]. Shareholder Dynamics - As of June 30, 2025, Haiprui had 26,300 shareholders, a decrease of 7.29% from the previous period. The average circulating shares per shareholder remained at 0 [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the eighth largest, holding 11.32 million shares, an increase of 6.38 million shares from the previous period [2].